Edition:
United Kingdom

STADA Arzneimittel AG (STAGn.DE)

STAGn.DE on Xetra

81.12EUR
10:05am BST
Change (% chg)

€0.02 (+0.02%)
Prev Close
€81.10
Open
€81.28
Day's High
€81.28
Day's Low
€80.86
Volume
4,574
Avg. Vol
43,252
52-wk High
€90.24
52-wk Low
€64.10

Summary

Name Age Since Current Position

Claudio Albrecht

2017 Chairman of the Executive Board, Chief Executive Officer

Guenter von Au

67 2017 Chairman of the Supervisory Board

Jens Steegers

38 2016 Deputy Chairman of the Supervisory Board, Employee Representative

Mark Keatley

2017 Chief Financial Officer, Member of the Executive Board

Ralph Grobecker

2017 Managing Director of OTC segment

Carsten Cron

47 2018 Member of the Management Board, Head Emerging Markets

Robert Knerr

2018 Member of the Management Board, Head of Business Development

Steffen Wagner

2018 Member of the Management Board, Head of Europe

Miguel Pagan

2018 Member of the Executive Board

Eric Cornut

61 2016 Member of the Supervisory Board

Halil Duru

58 2014 Member of the Supervisory Board, Employee Representative

Jan-Nicolas Garbe

37 2017 Member of the Supervisory Board

Benjamin Kunstler

39 2017 Member of the Supervisory Board

Ute Pantke

61 2014 Member of the Supervisory Board, Employee Representative

Bruno Schick

47 2017 Member of the Supervisory Board

Michael Siefke

51 2017 Member of the Supervisory Board

Frank Seiler

2017 IR Contact Officer

Biographies

Name Description

Claudio Albrecht

Dr. Claudio Albrecht was Chairman of the Executive Board, Chief Executive Officer at STADA Arzneimittel AG from September 27, 2017 to September 01, 2018. He was CEO and Chairman of generics manufacturer Actavis Group until its sale to Watson in 2012. He previously held the position of CEO at Ratiopharm Group. He started his career in the generics division of Sandoz.

Guenter von Au

Dr. Guenter von Au is Chairman of the Supervisory Board at STADA Arzneimittel AG effective September 25, 2017. He currently serves as Vice Chairman of the Board of Directors of Swiss chemicals group Clariant AG. He was CEO of Süd-Chemie AG from 2004 until 2012 and previously held leadership positions at Wacker Chemie AG for many years.

Jens Steegers

Mr. Jens Steegers is Deputy Chairman of the Supervisory Board, Employee Representative of STADA Arzneimittel AG from August 26, 2016. He is Member of the Supervisory Board and Employee Representative since June 4, 2014. He serves as Chairman of the Worker’s Council. He is Member of the Audit Committee at the Company.

Mark Keatley

Mr. Mark Keatley is Chief Financial Officer, Member of the Executive Board at STADA Arzneimittel AG effective September 27, 2017. He served as Chief Financial Officer at Actavis Group until its sale. Prior to joining Actavis, he held the position of Chief Financial Officer at Famar, a European contract manufacturer for the healthcare industry.

Ralph Grobecker

Dr. Ralph Grobecker is Managing Director of OTC segment of STADA Arzneimittel AG since May 1, 2017. He has decades of experience in the German pharmaceutical market and has developed outstanding expertise in the field of OTC medication in the various positions he has held. Since 2006, Dr. Grobecker worked at Merck, initially in the finance area as Head of R&D Controlling for Rx products and, from 2010 as CFO for the self-medication unit at Merck in Germany. From 2012 he assumed management responsibility for the German OTC business and was also responsible for the DACH region from last year. Prior to that, he worked for McKinsey & Company in the healthcare sector, among other positions.

Carsten Cron

Robert Knerr

Steffen Wagner

Dr. Steffen Wagner is Member of the Management Board, Head of Europe at STADA Arzneimittel AG from July 01, 2018. He was most recently Managing Director of Biogen Germany and will take charge of all European markets except for Germany, the United Kingdom and Russia.

Miguel Pagan

Mr. Miguel Pagan is Member of the Executive Board at STADA Arzneimittel AG from 2018. He is also responsible for Technical Operations. He was most recently Head of Global Technical Operations at SANDOZ and Global Head of Solids & Special Tech for overall Novartis. Before that, he was Head of all Operations of SANDOZ in Europe and India and previously Vice President of Americas Operations at Merck (MSD).

Eric Cornut

Dr. Eric Cornut is Member of the Supervisory Board at STADA Arzneimittel AG effective August 26, 2016. He is a Chairman of the Strategy Committee, He is an Independent Consultant. He has held Various Novartis-internal Directorships. He holds a Masters degree in law from University of California-Berkeley, USA for the year 1987 and Doctorate in Philosophy in Law from University of Basel, Switzerland for the year 1984.

Halil Duru

Mr. Halil Duru is Member of the Supervisory Board and Employee Representative of STADA Arzneimittel AG effective June 4, 2014. He is Member of the Human Resource Committee at the Company. He is Deputy Chairman of the Worker’s Council.

Jan-Nicolas Garbe

Benjamin Kunstler

Ute Pantke

Dr. Ute Pantke is Member of the Supervisory Board and Employee Representative of STADA Arzneimittel AG effective June 4, 2014. She serves as Director Special Brand Projects, Wettenberg. She is a Member of the Strategy Committee.

Bruno Schick

Michael Siefke

Frank Seiler